INTRODUCTION 44
Over 78 million United States adults were defined as obese in 2009-2010 using the WHO 45 BMI classification system, thus it is evident that obesity has become a substantial health problem 46 (17). Not only is obesity associated with a number of co-morbidities such as hypertension, 47 transferred into three regenerated cellulose 30 kDa molecular weight cutoff ultrafiltration devices 113 (Centrifree Centrifugal Filters, Millipore Corporation, Billerica, MA) and centrifuged at 2,000 x 114 g using a fixed angle rotor for 45 minutes at 10°C to obtain ultrafiltrate (C ultrafiltrate ). An aliquot 115 of serum was also retained at each corresponding time point for total drug concentration 116 determination at that time point (C total ). Protein binding was calculated using the following 117 equation: % protein binding = 100 -(100 x C ultrafiltrate / C total ). 118
Analytical procedures. Linezolid concentrations in serum and ultrafiltrate were determined 119 using a validated high-performance liquid chromatography (HPLC) assay at the Center for Anti-120
Infective Research & Development in Hartford, CT based on a previously published assay (5). 121
The serum assay was linear over a range of 0.2 to 30 µg/mL (r 2 = 1.00) For serum, the mean 122 interday coefficient of variability for the high (20 µg/ml) and low (0.5 µg/ml) quality control 123 samples were 4.4% and 3.8%, respectively; whereas, the respective mean intraday coefficient of 124 variability were 3.3% and 2.4%. The ultrafiltrate assay was linear over a range of 0.1 to 20 125 µg/mL (r7 models included parallel capacity-limited (non-renal) and first-order (renal) clearances (15), as 136 well as non-linear clearance that can be inhibited over time depending on the concentration in an 137 empirical inhibition compartment (19). The final model was selected based on the log 138 likelihood, Akaike information criterion, and the ability to accurately predict the observed 12 139 hour area under the curve after the 5 th dose. Weighting based on intra-day assay variance was 140 employed using a plot of the assay standard deviation (SD) versus measured linezolid 141 concentration, which was best described by the equation SD = γ(0.00189 + 0.0412*C), where C 142 is the linezolid concentration and γ was identified as 2.085. Mean values were used as the 143 measure of central tendency for population parameter estimates. Bayesian estimates were 144 obtained for each patient using the population-of-one utility within BigNPAG. The mean 145 weighted error was the estimate of bias. The bias-adjusted mean weighted squared error was 146 employed as the estimate of precision. AUCτ was calculated for each participant by simulating 147 the concentration time profile after 5 doses of linezolid 600mg every 12 hours using ADAPT 5 148 (8) . Table  170 1. 171 signifies that clearance can be inhibited to 85.5% of its original value over time. Fig. 2a  182 demonstrates the observed versus population predicted plots (using the mean parameter vector) 183 for linezolid concentrations in serum. The measures of bias and precision were acceptable for a 184 pre-Bayesian analysis. A single participant from the lower BMI group had observed linezolid 185 concentrations significantly greater than the rest of the population. Removing this patient's 186 concentration data resulted in mean population parameter estimates that were within 5% of the 187 total population estimates, therefore, this participant's data were retained in the analyses. For the morbidly obese BMI group (40-54.9 kg/m 2 ), the model predicted AUCτ was 108.5 ± 25.7 195 µg*h/mL. There was no difference in CL, Vc, Vd, or RCLF between BMI groups (Table 4) . 196
There was no significant relationship between total body weight and the observed AUCτ 197 exposure (Fig 3) . Finally, the relationship between CL, Vc, and Vd with body size descriptors is 198 listed in Table 5 The mean weight of the patients (146 ± 37 kg) included in this study was greater than that of our 241 population, and all patients had a total body weight >50% of their ideal body weight. While the 242 observed one hour concentration in the study was low, it is possible that a true peak was missed 243
given the sparse sampling design (i.e., samples were obtained only at 1, 6, and 12 h) and because 244 linezolid was administered orally. The sparse sampling would have also affected the reported 245 AUCτ in the study, which was 92 ± 33 µg*h/mL. A second study determined linezolid 246 pharmacokinetics in nine critically ill patients receiving normal to high doses of intravenous 247 linezolid ranging from 600mg every 12 h to 900 mg every 8 h (7). The mean TBW and BMI ofinfusion and a second concentration collected at the trough; a peak was estimated by back 251 extrapolating assuming 1-compartment linear pharmacokinetics. After normalizing to a dose of 252 600 mg every 8 h, the investigators report a 24 hour AUC in these patients of 211 ± 102 253 µg*h/mL. For comparison, a steady-state 24 hour AUC for 600mg every 8 hours using our mean 254 population pharmacokinetic parameters results in a value of 324 µg*h/mL. Again, there may be 255 several reasons, unrelated to obesity, why AUC exposure for such a dosing regimen would be 256 lower in the second study's population. The investigators assumed a one-compartment, linear 257 model when estimating the peak concentration and AUC exposure, thus the true peak may have 258 been underestimated, and clearance would be reduced over additional days of therapy. Secondly, 259 the study population was infected, critically ill patients. to non-obese patients. Additionally, BMI is a poor predictor for adjusting dosing regimens in the 289 obese population, and a more accurate descriptor of body mass should be utilized. Finally, a 290 correlation between Vd and several body weight descriptors was observed suggesting that 291 concentrations in patients weighing greater than the participants included in this study may be 292 altered as described by previous studies. 293
We thank Lee Steere, RN for his efforts in IV therapy services and drug administration. 296
Additionally we thank Christina Sutherland for conducting all HPLC analyses and for assisting 297 with the coordination of study activities. We acknowledge Seth T. Housman 
